Richard Kimes has joined Reva Medical as the company’s senior vice president of operations. He is now responsible for leading manufacturing-related activities in support of the launch of sirolimus-eluting bioresorbable coronary scaffold, Fantom, in international markets.
Fantom is due for commercial launch in the first half for 2017, following confirmation of positive clinical data and receipt of CE mark approval.
Kimes has more than 25 years of experience in the medical device industry. He served as senior vice president of Operations for Volcano Corporation from June 2009 to May 2013, where he developed and executed the operations strategy, including the start-up of international manufacturing. Previously, he spent 18 years at Guidant Corporation (now Abbott Laboratories) where he held increasing roles of responsibility before becoming director of Operations and Process Engineering for Drug-Eluting Stents. In this role, he was responsible for developing and implementing manufacturing operations to support clinical trials, regulatory approvals, and commercial sales. He has also held senior operations positions at mNemoscience GmbH and Elixir Medical Corporation.
“We are excited to bring Rick on board to fill this important role for the Company,” comments Reggie Groves, Reva’s chief executive officer. “His strong operational expertise and demonstrated success transferring products from a clinical stage to full manufacturing make him ideally suited to lead Reva’s efforts to develop a world-class operations organization.”
